Core Viewpoint - The announcement highlights the acceptance of the new drug application for Madaxanovir tablets by the National Medical Products Administration (NMPA) in China, indicating a significant step forward in the treatment of influenza for adults and adolescents without complications [1][2]. Group 1: Drug Development - The collaboration between the company and Jiaxing Antikang Biotechnology Co., Ltd. focuses on the development of Madaxanovir, an antiviral drug aimed at treating influenza [1]. - Madaxanovir is characterized as an inhibitor of the polymerase acidic protein (PA) endonuclease activity, which is crucial for the replication of the influenza virus [2]. Group 2: Drug Advantages - Madaxanovir presents several advantages, including no central nervous system side effects, oral absorption unaffected by food, and a higher safety dosage compared to existing treatments [2]. - The drug requires only a single oral dose to effectively block the replication of the influenza virus within 24 hours, potentially offering significant convenience for patients, including children [2].
先声药业：玛氘诺沙韦片新药上市申请获国家药监局受理